Weigelt J A
Department of Surgery, St. Paul-Ramsey Medical Center, University of Minnesota, 55101, USA.
Am J Surg. 1998 Dec;176(6A Suppl):4S-7S. doi: 10.1016/s0002-9610(98)00212-8.
Postoperative infection remains a complication of surgical procedures, resulting in increased morbidity, mortality, and cost. The frequent polymicrobial etiology and emerging patterns of resistance continue to compromise cure rates. Although quinolones have many attractive properties for the surgical setting, combination therapy is routinely indicated for appropriate coverage. Advanced-generation quinolones, such as trovafloxacin, offer an increased antimicrobial spectrum, including activity against important surgical pathogens, and longer elimination half-lives. These newer agents may be used intravenously or orally as once-daily single-agent therapy for surgical prophylaxis, and in place of combination therapy for complex intra-abdominal and pelvic infections.
术后感染仍然是外科手术的一种并发症,会导致发病率、死亡率增加以及成本上升。常见的多种微生物病因和新出现的耐药模式持续影响治愈率。尽管喹诺酮类药物在外科手术环境中有许多吸引人的特性,但通常仍需联合治疗以实现适当的覆盖范围。新一代喹诺酮类药物,如曲伐沙星,具有更广的抗菌谱,包括对重要外科病原体的活性,且消除半衰期更长。这些新型药物可静脉注射或口服,作为手术预防的每日一次单药治疗,也可替代联合治疗用于复杂的腹腔内和盆腔感染。